This is an open-label study of 12 months of dosing with ACH-0144471. The study will enroll patients with biopsy-confirmed C3G or IC-MPGN who meet eligibility criteria for this study. There will be a multi-step screening process. At the initial screening visit, all screening eligibility assessments, except the renal biopsy, will be performed. If the subject remains eligible based on the results from the initial screening visit, then arrangements can be made for renal biopsy and vaccinations. The initial screening visit must occur no more than 75 days before the first dose date. The renal biopsy must occur no more than 30 days before the first dose, but will be targeted to occur approximately two weeks prior to the first dose of ACH-0144471.

You may be eligible for this study if you meet the following criteria:

• Conditions: C3,IC-MPGN
• Age: 17 years - 65 years
• Gender: All